Literature DB >> 6609414

Differences in the production of and/or the response to interleukin-2 by T lymphocytes from patients with the various connective tissue diseases.

J Alcocer-Varela, A Laffón, D Alarcón-Segovia.   

Abstract

We have studied the production of and the response to interleukin-2 (IL-2) by blood T lymphocytes from 83 untreated patients with six connective tissue diseases, each patient with a healthy age/sex matched control. SLE patients had markedly decreased production of IL-2, both when elicited with phytohemagglutinin (PHA) and when promoted by autologous mixed lymphocyte reaction (AMLR). They also had decreased response to IL-2. Conversely, patients with scleroderma had normal production of IL-2 with both stimuli and their lymphocytes responded to IL-2 similarly to, or even better than, controls. Patients with mixed connective tissue disease had decreased production of IL-2 upon PHA stimulation but it was normal in AMLR systems. Response to IL-2 was moderately diminished. Patients with rheumatoid arthritis showed moderately decreased production of Il-2 with both stimuli but a normal response to Il-2. Patients with Sjögren's syndrome had similar, but less marked defects than those of SLE. Patients with dermato-polymyositis showed decreased production of IL-2 in AMLR but normal production of IL-2 in response to PHA as well as normal response to IL-2. The differences found between the various connective tissue diseases support the notion that the T cell dysregulation that results from or leads to "autoimmunity" in them is peculiar to each disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609414     DOI: 10.1007/bf00683884

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  41 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

Review 3.  Glucocorticoids and immune responses.

Authors:  G R Crabtree; S Gillis; K A Smith; A Munck
Journal:  Arthritis Rheum       Date:  1979-11

4.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

5.  Suppressor cell loss and dysfunction in mixed connective tissue disease.

Authors:  D Alarcón-Segovia; A Ruíz-Arguelles
Journal:  Arthritis Rheum       Date:  1980-03

6.  Self recognition by autologous mixed lymphocyte reaction-primed cells.

Authors:  K Tomonari; A Wakisaka; M Aizawa
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

7.  Differences in the kinetics of the autologous mixed lymphocyte reaction between the various connective tissue diseases.

Authors:  A Laffón; J Alcocer-Varela; D Alarcón-Segovia
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

8.  Articular manifestations of mixed connective tissue disease.

Authors:  F Ramos-Niembro; D Alarcón-Segovia; J Hernández-Ortíz
Journal:  Arthritis Rheum       Date:  1979-01

9.  T lymphocytes of young and aged rats. II. Functional defects and the role of interleukin-2.

Authors:  S C Gilman; J S Rosenberg; J D Feldman
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422

10.  Abnormalities of T lymphocyte subsets in patients with progressive systemic sclerosis (PSS, scleroderma).

Authors:  T Inoshita; T L Whiteside; G P Rodnan; F H Taylor
Journal:  J Lab Clin Med       Date:  1981-02
View more
  9 in total

1.  The effect of the immunomodulator agent AS101 on interleukin-2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody.

Authors:  M Blank; B Sredni; M Albeck; E Mozes; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

2.  A defect in immunoregulatory synovial fluid T cells in Behçet's syndrome.

Authors:  J Alcocer-Varela; A Laffon; C Abud-Mendoza; D Alarcon-Segovia
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

3.  Modulation of human T cell functions by surface sulphydryl groups: differential effects on IL-2 production and responsiveness.

Authors:  S Smith; C H Brown-Galatola; N D Hall
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

4.  Diagnosis and risk stratification in patients with anti-RNP autoimmunity.

Authors:  M F Carpintero; L Martinez; I Fernandez; A C Garza Romero; C Mejia; Y J Zang; R W Hoffman; E L Greidinger
Journal:  Lupus       Date:  2015-03-02       Impact factor: 2.911

5.  Differences in the kinetics of the autologous mixed lymphocyte reaction between the various connective tissue diseases.

Authors:  A Laffón; J Alcocer-Varela; D Alarcón-Segovia
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

6.  Natural killer cell-mediated activity in mixed connective tissue disease and its response to induction by interleukin-2.

Authors:  R González-Amaro; J Alcocer-Varela; E Martínez-Cordero; D Alarcón-Segovia
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

7.  Correlation of disease activity and drug therapy with the autologous mixed lymphocyte reaction in rheumatoid arthritis.

Authors:  S M Cross; R A Hazelton
Journal:  Ann Rheum Dis       Date:  1985-04       Impact factor: 19.103

8.  Deficient interleukin 2 production in rheumatoid arthritis: association with active disease and systemic complications.

Authors:  G D Kitas; M Salmon; M Farr; J S Gaston; P A Bacon
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

9.  Functional Analysis of Dendritic Cells Generated from T-iPSCs from CD4+ T Cell Clones of Sjögren's Syndrome.

Authors:  Mana Iizuka-Koga; Hiromitsu Asashima; Miki Ando; Chen-Yi Lai; Shinji Mochizuki; Mahito Nakanishi; Toshinobu Nishimura; Hiroto Tsuboi; Tomoya Hirota; Hiroyuki Takahashi; Isao Matsumoto; Makoto Otsu; Takayuki Sumida
Journal:  Stem Cell Reports       Date:  2017-05-09       Impact factor: 7.765

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.